spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

IONTAS to generate antibodies with favourable, binding and expression properties using their Mammalian Display Antibody Discovery Platform

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

IONTAS’ platform allows for the construction of large libraries of monoclonal cell lines each displaying a different IgG-formatted antibody on the cell surface. Novel binders can be isolated from the libraries by using fluorescence-activated cell sorting on the basis of antigen binding. Importantly, the system also has the potential to identify clones with development liabilities, such as self-aggregation, during the initial discovery phase.

Dr John McCafferty, CEO at IONTAS, commented: “Historically the consideration of developability issues have been addressed after selection of drug lead molecules. Our Mammalian Display Platform not only allows direct screening of millions of clones for binding affinity and specificity, but also has the potential for early identification of developability issues such as product precipitation. Such issues can derail product development resulting in significant losses in time and money.”

ENDS

IONTAS Ltd
Neil Butt, Chief Business Officer
Tel: +44 1223 750801
bd@iontas.co.uk

Zyme Communications
Lorna Cuddon
Tel: +44 (0)1223 968 920
lorna.cuddon@zymecommunications.com

About IONTAS
www.iontas.co.uk
IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS has developed proprietary antibody discovery platforms including Mammalian Display where full IgG antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; and, KnotBody technology which facilitates the targeting of antibodies to ion channels, GPCRs and proteases.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>


White Papers

The Process of Informed Consent (written by ACRP)

CenterWatch

Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >>

Industry Events

BioProcess International European Summit

23-25 April 2018, RAI, Amsterdam

Bringing together 900+ attendees from all major departments in bioprocessing: Cell Culture, Downstream, Manufacturing, Vaccines, Viral Safety and Cell Line Development this April in Amsterdam, Europe’s largest bioprocessing event BPI Europe 2018 will provide you with the latest advice on how optimise bioprocessing through connecting science, technology and business.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement